stoxline Quote Chart Rank Option Currency Glossary
  
Regencell Bioscience Holdings Limited (RGC)
16.93  0.33 (1.99%)    12-15 15:59
Open: 16.81
High: 17.91
Volume: 110,319
  
Pre. Close: 16.6
Low: 16.3
Market Cap: 8,372(M)
Technical analysis
2025-12-15 4:41:52 PM
Short term     
Mid term     
Targets 6-month :  21.19 1-year :  24.76
Resists First :  18.14 Second :  21.19
Pivot price 14.38
Supports First :  13.31 Second :  10.32
MAs MA(5) :  16.73 MA(20) :  13.98
MA(100) :  14.6 MA(250) :  0
MACD MACD :  0.7 Signal :  0.2
%K %D K(14,3) :  84 D(3) :  81.9
RSI RSI(14): 65.7
52-week High :  83.59 Low :  0.09
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ RGC ] has closed below upper band by 23.8%. Bollinger Bands are 132% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 17.93 - 18.03 18.03 - 18.12
Low: 16.08 - 16.18 16.18 - 16.28
Close: 16.78 - 16.95 16.95 - 17.1
Company Description

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Headline News

Mon, 15 Dec 2025
Will DOJ Probe Into Trading And Accounting Practices Change Regencell Bioscience Holdings' (RGC) Narrative? - simplywall.st

Fri, 12 Dec 2025
Regencell Bioscience (NASDAQ:RGC) Stock Price Up 5.4% - Should You Buy? - MarketBeat

Thu, 11 Dec 2025
Bragar Eagel & Squire, P.C. Continues Investigations into - GlobeNewswire

Fri, 05 Dec 2025
Regencell Bioscience (NASDAQ:RGC) Stock Price Up 17.9% - Time to Buy? - MarketBeat

Fri, 05 Dec 2025
Regencell Bioscience: Material Weaknesses Add To Woes (NASDAQ:RGC) - Seeking Alpha

Mon, 24 Nov 2025
This Stock Soared 9,800% in 2025. Here's 1 Key Reason Why Investors Are Piling In (Spoiler: It's Regencell Bioscience Holdings (RGC) Stock) - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 494 (M)
Shares Float 18 (M)
Held by Insiders 88.5 (%)
Held by Institutions 0.1 (%)
Shares Short 1,180 (K)
Shares Short P.Month 1,290 (K)
Stock Financials
EPS -0.01
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -33.3 %
Return on Equity (ttm) -54.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.01
Qtrly Earnings Growth 0 %
Operating Cash Flow -3 (M)
Levered Free Cash Flow -2 (M)
Stock Valuations
PE Ratio -1693.01
PEG Ratio 0
Price to Book value 1693
Price to Sales 0
Price to Cash Flow -2691.87
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android